NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $7.13 +0.32 (+4.70%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$7.13 0.00 (0.00%) As of 10/8/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PHAT alerts:Sign Up Key Stats Today's Range$6.68▼$7.1850-Day Range$6.70▼$9.5852-Week Range$6.52▼$18.31Volume1.33 million shsAverage Volume1.41 million shsMarket Capitalization$576.82 millionP/E RatioN/ADividend YieldN/APrice Target$21.25Consensus RatingModerate Buy Company Overview Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s portfolio is centered on vonoprazan, a potassium-competitive acid blocker designed to suppress gastric acid production and provide an alternative to traditional proton pump inhibitors. Phathom markets vonoprazan in the United States under the brand name Voquezna. The product is approved for the healing and maintenance of healing of erosive esophagitis, relief of associated heartburn, and treatment of heartburn related to non-erosive gastroesophageal reflux disease. Voquezna is also approved, in combination with antibiotics, for the eradication of Helicobacter pylori, a bacterium associated with peptic ulcers and other gastrointestinal conditions. Phathom was established in 2018 and obtained U.S. rights to develop and commercialize vonoprazan through an agreement with Takeda Pharmaceutical Company. The company is headquartered in Buffalo Grove, Illinois, and is led by Chief Executive Officer Terrie Curran. Its commercial activities are primarily focused on the U.S. gastrointestinal market.AI Generated. May Contain Errors. Read More Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScorePHAT MarketRank™: Phathom Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 246th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPhathom Pharmaceuticals has a consensus price target of $21.25, representing about 198.0% upside from its current price of $7.13.Amount of Analyst CoveragePhathom Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($0.27) to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.85% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 9.11.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 6.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.25 News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders9.33% of the stock of Phathom Pharmaceuticals is held by insiders.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAT Stock News HeadlinesPhathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingOctober 8 at 8:00 AM | globenewswire.comEyepoint Pharmaceuticals (NASDAQ:EYPT) and Phathom Pharmaceuticals (NASDAQ:PHAT) Head-To-Head AnalysisOctober 7 at 3:59 AM | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | Investors Alley (Ad)Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 6 at 4:15 AM | americanbankingnews.comReviewing Traws Pharma (NASDAQ:TRAW) & Phathom Pharmaceuticals (NASDAQ:PHAT)October 1, 2026 | americanbankingnews.comPhathom Pharmaceuticals Starts Registrational Phase 3 Voquezna StudySeptember 30, 2026 | finance.yahoo.comPhathom Pharmaceuticals, Inc. Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERDSeptember 29, 2026 | marketscreener.comMPhathom Pharmaceuticals avvia la fase 3 per VOQUEZNA nella NERDSeptember 29, 2026 | it.investing.comSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $16.59 at the start of the year. Since then, PHAT shares have decreased by 57.0% and is now trading at $7.13. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced its earnings results on Thursday, February, 26th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to analysts' expectations of $57.44 million. Read the conference call transcript. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $182 million in an initial public offering on Friday, October 25th 2019. The company issued 9,563,157 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings2/26/2026Today10/09/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, PHAT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PHAT CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees371Year Founded2018Price Target and Rating Average Price Target for Phathom Pharmaceuticals$21.25 High Price Target$28.00 Low Price Target$10.00 Potential Upside/Downside+198.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$221.25 million Net Margins-41.34% Pretax Margin-41.34% Return on EquityN/A Return on Assets-20.81% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.87 Sales & Book Value Annual Sales$175.11 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book Value($6.14) per share Price / Book-1.16Miscellaneous Outstanding Shares80,900,000Free Float73,353,000Market Cap$576.82 million OptionableOptionable Beta0.50 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PHAT) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
